Figure 1.

VIT-2763 did not impair the ability of deferasirox (DFX) to reduce iron overload in Hbb^th3/+ mice. (a) The combination of VIT-2763 with DFX resulted in a similar reduction in the liver iron concentration in Hbb^th3/+ mice as DFX treatment alone. (b) Improved kidney iron reduction by the combination of VIT-2763 and DFX. (c) Serum iron levels in mice receiving VIT-2763 alone or in combination with DFX. (d) Transferrin saturation (TSAT) levels in mice treated with VIT-2763 alone or in combination with DFX. Results represent the mean ± SD. Statistical significance was determined using one-way ANOVA with Dunnett’s multiple-comparison test. * p < 0.05 and *** p < 0.001. # p < 0.05 depicts a comparison to the group treated with the combination of VIT-2763 and DFX. Wild-type (WT) littermates received both vehicles and were included as controls. n = 10–13 mice per group.